AKT1

RAC-alpha serine/threonine-protein kinase · P31749 · AKT1 on Sugi Atlas →

204,435 patent compounds predicted against AKT1, 114,454 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Uprosertib (SCHEMBL168584)	1.00	20/20
Gamma-Tocopherol (SCHEMBL39640)	0.91	13/20
Gamma-Tocopherol (SCHEMBL120346)	0.91	13/20
SCHEMBL74101	0.91	13/20
SCHEMBL65343	0.53	13/20
Afuresertib (SCHEMBL187686)	1.00	12/20
SCHEMBL31499	0.44	11/20
Perifosine (SCHEMBL93872)	1.00	10/20
SCHEMBL188526	0.63	10/20
SCHEMBL25391	0.53	10/20
Trifluoroacetic Acid (SCHEMBL98792)	0.50	9/20
SCHEMBL31491	0.41	9/20
SCHEMBL31500	0.36	8/20
Alpha-Tocopherol (SCHEMBL124961)	0.77	7/20
SCHEMBL78264	0.49	7/20
SCHEMBL149982	0.49	7/20
SCHEMBL154600	0.40	7/20
Sulfamethizole (SCHEMBL26453)	0.68	6/20
SCHEMBL99315	0.50	6/20
SCHEMBL181860	0.46	6/20

Clinical trials — most relevant to AKT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC	PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)	PHASE2	COMPLETED
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a AKT1 binder may also engage these)

Protein	Name	Similarity
P31750	—	1.000	P31750 →
P47196	—	1.000	P47196 →
Q98TY9	—	1.000	Q98TY9 →
Q01314	—	1.000	Q01314 →
P31748	—	0.999	P31748 →
Q9WUA6	—	0.991	Q9WUA6 →
Q7ZX15	—	0.990	Q7ZX15 →
Q63484	—	0.990	Q63484 →
P47197	—	0.988	P47197 →
AKT2	RAC-beta serine/threonine-protein kinase	0.988	landscape →
Q60823	—	0.987	Q60823 →
AKT3	RAC-gamma serine/threonine-protein kinase	0.986	landscape →
Q6IP76	—	0.985	Q6IP76 →
Q6ZI44	—	0.966	Q6ZI44 →
Q5N942	—	0.963	Q5N942 →
Q9C958	—	0.962	Q9C958 →
Q9FFP9	—	0.962	Q9FFP9 →
Q3UMW7	—	0.962	Q3UMW7 →
Q66H84	—	0.960	Q66H84 →
P0C5D6	—	0.960	P0C5D6 →
A2ZAB5	—	0.960	A2ZAB5 →
Q39192	—	0.960	Q39192 →
Q7XQP4	—	0.960	Q7XQP4 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.959	landscape →
Q9M9E9	—	0.958	Q9M9E9 →
Q02066	—	0.958	Q02066 →
P43292	—	0.958	P43292 →
Q75H77	—	0.958	Q75H77 →
GRK4	G protein-coupled receptor kinase 4	0.957	landscape →
Q91Y86	—	0.957	Q91Y86 →